![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.40 | 13.80 | 15.00 | 14.40 | 14.40 | 14.40 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLLAI
RNS Number : 5436E
LungLife AI, INC
08 July 2021
LungLife AI, Inc.
("LungLife" or the "Company")
Director/PDMR Notification
LungLife (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each ("Common Shares") undertaken by directors.
The transactions were made in connection with the placing of new Common Shares in the capital of the Company as part of the Company's admission to trading on AIM.
Roy Davis, Non-Executive Chair, has today purchased 14,204 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Davis now holds 14,204 Common Shares, representing approximately 0.06% of the outstanding share capital of the Company.
In addition, Andrew Boteler, Non-Executive Director, has today purchased 5,681 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Boteler now holds 5,681 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.
The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Roy Davis 2) Andrew Boteler --------------------- --------------------------------------------- 2 Reason for the notification -------------------------------------------------------------------- a) Position/status 1) Non-Executive Chairman 2) Non-Executive Director --------------------- --------------------------------------------- b) Initial notification 1) Initial notification /Amendment 2) Initial notification --------------------- --------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------- a) Name LungLife AI, Inc. --------------------- --------------------------------------------- b) LEI 549300VBVDIF0Y3OVI38 --------------------- --------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted -------------------------------------------------------------------- a) Description Common shares of $0.0001 each in the capital of the financial of the Company instrument, type of instrument ISIN: USU5500L1045 Identification code --------------------- --------------------------------------------- b) Nature of the Purchase of Common Shares transaction --------------------- --------------------------------------------- c) Price(s) and Price No. of shares volume(s) 1) 176.0p 1) 14,204 2) 176.0p 2) 5,681 -------------- --------------------- --------------------------------------------- d) Aggregated N/a - single transaction information - Aggregated volume - Price --------------------- --------------------------------------------- e) Date of the 8 July 2021 transaction --------------------- --------------------------------------------- f) Place of the London Stock Exchange, AIM transaction --------------------- ---------------------------------------------
- Ends -
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970 & Broker) Daniel Adams / Virginia Bull / Cameron MacRitchie Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDKOBNBBKBNOK
(END) Dow Jones Newswires
July 08, 2021 03:00 ET (07:00 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions